Atropos Evidence™ Network Grows to Over 300 Million Patients - Becoming Industry’s Largest Federated Healthcare Data Network - and Announces Additional Customer
2024年6月24日 - 10:55PM
ビジネスワイヤ(英語)
Atropos Health today announced the expansion of the Atropos
Evidence Network to include two new partners, adding to the growing
number of datasets and use cases for the Atropos Evidence Network
including oncology and international. The company additionally
announced a new customer - Translational Drug Development (TD2) -
which will gain immediate access to clinical insights generated
from Atropos Health’s new data contributors.
The Atropos Evidence Network expansion signifies the company’s
commitment to life science and healthcare organizations who are
seeking evidence for decision-making in medicine. With access to
more real-world data (RWD), partners can access the right data for
each question backed by the Atropos Real World Fitness Score™,
which evaluates the appropriateness and quality of data for each
question. These additional datasets also increase the opportunity
for partners to find more “fit-for-purpose” data.
“We are excited to welcome these new partners to the Atropos
Evidence Network,” said Dr. Brigham Hyde, CEO and co-Founder of
Atropos Health. “As the largest federated healthcare data network,
our commitment to members is to reduce data security and identity
management risks, bring them great tools to add automation,
efficiency, and transparency to their own processes, and allow them
to create value for the significant investments they have made in
data quality and data enrichment. All of this is with the end user
in mind; end users who will drive the scale of evidence generation
needed to enable personalized evidence for everyone.”
With the addition of Forian, Syndesis Health and the recently
announced Norstella partnership the Atropos Evidence Network
continues to expand with more of the high-quality datasets needed
to generate actionable insights - and with Real World Data Score™
(RWDS) & Real World Fitness Score™ (RWFS) users can select the
dataset that is the most suitable to answer each question. Data
contributors also receive transparent, analytically driven feedback
on usage and their own data quality and strengths. The Atropos
Evidence Network creates a market for data holders to expand the
reach of these de-identified assets to a broader audience. Atropos
Health is the connection between real-world evidence (RWE) and
actionable clinical analytics.
“Our partnership with Atropos Health underscores our commitment
to advancing precision medicine by leveraging Syndesis Health’s
extensive datasets,” said Josh Sutton, CEO of Syndesis Health.
“With data spanning 15 countries outside of the US and
approximately 35 million patients, we are uniquely positioned to
ensure that the advancements in precision medicine reflect both
geographic and ethnic diversity. By integrating these diverse
datasets into the Atropos Evidence Network, we can generate more
comprehensive and inclusive real-world evidence, ultimately leading
to more personalized and effective treatments for patients around
the globe.”
The Atropos Evidence Network operates on GENEVA OS™ (Generative
Evidence Acceleration Operating System), a federated model, forming
secure, cloud-based connections between healthcare data proprietors
and clinical insight seekers across the healthcare ecosystem.
De-identified data doesn’t change hands - institutional members of
the network, such as a physician or researcher, can pose clinical
questions to a variety of datasets. Within 48 hours, the user
receives a novel retrospective observational study in response.
New customer TD2 will utilize Atropos Health to improve patient
outcomes, develop protocols and clinical trial evidence. TD2 will
leverage the Green Button Informatics Consult Service, the Atropos
Evidence Network and Alexandria™ (fka Atropos Evidence™ Library) to
develop and test clinical trial designs with the goal of optimizing
clinical study execution.
“We are thrilled to partner with Atropos Health and gain access
to the Atropos Evidence Network,” said Stephen Gately, PhD,
President and CEO of TD2. “This collaboration will enable us to
leverage high-quality real-world data to optimize clinical trial
designs and improve patient outcomes. By integrating Atropos
Health’s innovative tools and extensive data sets, we can
accelerate the development of new oncology therapies and bring them
to patients with greater precision and speed.”
Forian and Syndesis Health bring a breadth and depth of rich
datasets to the Atropos Evidence Network. The Atropos Evidence
Network already includes an impressive slate of leaders in the
healthcare data ecosystem, including Stanford, Mayo and recently
announced Arcadia. When it comes to data science and AI
applications for clinical Q&A, Atropos Health answers clinical
questions fast, transparently, and with previously unavailable
information and data, enabling studies to be run on multiple
datasets at once.
About Atropos Health
Atropos Health is the developer of GENEVA OS™ , the operating
system for rapid healthcare evidence across a robust network of
real-world data. Healthcare and life science organizations work
with Atropos Health to close evidence gaps from bench to bedside,
improving individual patient outcomes with data-driven care,
expediting research that advances the field of medicine, and more.
We aim to transform healthcare with timely, relevant real-world
evidence.
To learn more about Atropos Health, visit www.atroposhealth.com
or connect through LinkedIn or follow on X (Twitter)
@AtroposHealth.
About Forian
Forian provides a unique suite of data management capabilities
and proprietary information and analytics solutions to optimize and
measure operational, clinical and financial performance for
customers within the traditional and emerging life sciences and
healthcare payer and provider segments. Forian has industry leading
expertise in acquiring, integrating, normalizing and
commercializing large scale healthcare data assets. Forian's
information products overlay sophisticated data management and data
science capabilities on top of a comprehensive clinical data lake
to identify unique relationships, create distinctive information
assets and generate proprietary insights. For more information,
please visit the Company's website at www.forian.com.
About Syndesis Health, Inc.
Syndesis is the data and technology catalyst to a
multi-continent network of healthcare and life sciences
organizations. Its primary aim is to enhance global health outcomes
and equity through its secure data platform, Syntium, and the
Syndesis Health Network, a member community promoting research
collaboration, information sharing, and access to common tools. For
more information, please visit the company's website at
www.syndesis.com.
About TD2
TD2 is a leader in precision oncology, providing innovative
services for improved drug development. Using a dedicated, expert
team with broad experience and understanding in cancer medicine,
TD2 is uniquely positioned to support accelerated development of
novel therapeutics. Rigorous and high-throughput translational
preclinical development services, combined with regulatory affairs
expertise, enables customized clinical trial design and execution.
Our unique Oncology Ecosystem encourages the timely selection of
patient populations who are most likely to benefit from a new
agent, and the rapid identification of clinically significant
endpoints. TD2 is committed to reducing the risks and uncertainty
inherent in the drug development process with the ultimate goal of
accelerating patient access to promising treatments. For more
information, visit www.TD2inc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240624674079/en/
Bruno Solari bruno@solcomms.co